MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness by C. Evangelisti et al.
The FASEB Journal • Research Communication
MiR-128 up-regulation inhibits Reelin and DCX
expression and reduces neuroblastoma cell motility
and invasiveness
Cristina Evangelisti,*,1 Maria Carolina Florian,†,1 Isabella Massimi,‡ Carlo Dominici,§,,¶
Giuseppe Giannini,‡ Silvia Galardi,* Maria Cristina Bue`,* Simone Massalini,*
Heather P. McDowell,§,# Elio Messi,† Alberto Gulino,‡,** Maria Giulia Farace,* and
Silvia Anna Ciafre`*,2
*Department of Experimental Medicine and Biochemical Sciences, University of Rome “Tor
Vergata,” Rome, Italy; †Dipartimento di Endocrinologia, Fisiopatologia e Biologia Applicata, Facolta`
di Farmacia, Universita` degli Studi di Milano, Milan, Italy; ‡Department of Experimental Medicine
and §Department of Pediatrics, University of Rome “La Sapienza,” Rome, Italy; Laboratory of
Oncology, Bambino Gesu` Children’s Hospital, Rome, Italy; ¶Division of Child Health, School of
Reproductive and Developmental Medicine, Liverpool University, Liverpool, UK; #Division of
Oncology, Royal Liverpool Children’s National Health Service Trust Alder Hey, Liverpool, UK; and
**Neuromed Institute, Pozzilli, Italy
ABSTRACT MicroRNAs are a class of sophisticated
regulators of gene expression, acting as post-transcrip-
tional inhibitors that recognize their target mRNAs
through base pairing with short regions along the 3UTRs.
Several microRNAs are tissue specific, suggesting a spe-
cialized role in tissue differentiation or maintenance, and
quite a few are critically involved in tumorigenesis. We
studied miR-128, a brain-enriched microRNA, in retinoic
acid-differentiated neuroblastoma cells, and we found
that this microRNA is up-regulated in treated cells, where
it down-modulates the expression of two proteins in-
volved in the migratory potential of neural cells: Reelin
and DCX. Consistently, miR-128 ectopic overexpression
suppressed Reelin and DCX, whereas the LNA antisense-
mediated miR-128 knockdown caused the two proteins to
increase. Ectopic miR-128 overexpression reduced neuro-
blastoma cell motility and invasiveness, and impaired cell
growth. Finally, the analysis of a small series of primary
human neuroblastomas showed an association between
high levels of miR-128 expression and favorable features,
such as favorable Shimada category or very young age at
diagnosis. Thus, we provide evidence for a role for
miR-128 in the molecular events modulating neuroblas-
toma progression and aggressiveness.—Evangelisti, C.,
Florian, M. C., Massimi, I., Dominici, C., Giannini, G.,
Galardi, S., Bue`, M. C., Massalini, S., McDowell, H. P.,
Messi, E., Gulino, A., Farace, M. G., Ciafre`, S. A. MiR-128
up-regulation inhibits Reelin and DCX expression and
reduces neuroblastoma cell motility and invasiveness.
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Micrornas are small (22 nt), noncoding RNAs that
act as negative regulators of gene expression at a
post-transcriptional level (1). Their regulatory activity is
performed via either the degradation of their specific
target mRNAs or the inhibition of mRNA translation
(2, 3). In most cases, animal microRNAs bind to their
target mRNAs through the recognition of complemen-
tary sequences located in the 3UTRs of mRNAs. The
minimal requirement allowing functional binding of a
microRNA to its target mRNA is usually represented by
a short sequence in the 3UTR that is perfectly comple-
mentary to nucleotides 2–8 at the 5 of the microRNA
itself. The interaction between this region of the
microRNA (called the “seed” region) and its comple-
mentary ones along a mRNA 3UTR is one of the key
parameters taken into account by the commonly ac-
cepted prediction algorithms employed to identify
which mRNAs can be regulated by one microRNA (4).
Because of the very short region of complementarity
that governs the functional interaction between a
microRNA and its targets, it is easy to understand how
one single microRNA can hit many different target
mRNAs and can perform its regulatory action in differ-
ent ways by “choosing” distinct targets, depending on
the specific cell environment where it is functioning (5,
6). The expression of some microRNAs can be ubiqui-
tous, but for others, a high specificity is well docu-
mented. MicroRNAs, which are enriched or even selec-
tively expressed only in the central nervous system
(CNS), represent undoubtedly the largest class of
tissue-specific microRNAs: a surprisingly higher num-
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ber of unique microRNAs have been isolated from
neuronal tissues or cell lines than from any other cell
type (7). Among these, miR-128 is a brain-enriched
microRNA, which is transcribed from two gene cop-
ies located on chromosomes 2 and 3. These two
genes, named miR-128 –1 and miR-128-2, respec-
tively, produce two microRNAs that are identical in
their mature forms.
Although first microRNAs were discovered relatively
recently (8, 9), much research has been performed
demonstrating their key role in normal development
and cancer. Our group has previously shown that
miR-128 is significantly down-regulated in glioblas-
toma multiforme (GBM), a highly malignant CNS
tumor (10).
Neuroblastoma is the most frequently occurring solid
tumor in childhood and derives from precursor cells of
the ganglionic lineage of the sympathetic nervous
system (SNS) (11, 12). It is a highly lethal malignancy,
accounting for around 15% of all pediatric oncology
deaths. Approximately half of the cases are classified as
high risk, with overall survival rates of 40% despite
intensive multimodal treatment (13), and are charac-
terized by a propensity to metastasize, especially to
bone, bone marrow, and distant lymph nodes (11).
Despite many advances in understanding the molecular
basis of this neoplasm, the molecular pathways leading
to neuroblastoma development remain obscure, and a
better elucidation of the molecular features of this
tumor is mandatory.
DCX, the protein product of the gene doublecortin,
located on chromosome X, is a microtubule-associated
protein required for neuroblastic migration during
cerebral cortex development (14). DCX expression in
migrating neurons spans from embryonic to postnatal
development, while in adult rodents and humans, only
a few cells express this protein, notably those located in
brain regions where neurogenesis is retained, such as
the hippocampus or the subventricular zone of the
lateral ventricular walls (15–18). DCX expression is also
detectable in some tumors of the nervous system, such
as GBM and neuroblastoma. In GBM, DCX expression
is associated with a poor outcome and has been pro-
posed as a marker of a migratory state of tumor cells
(19–21). In neuroblastoma, DCX expression has been
demonstrated in primary tumors and metastatic sites
disease (22); moreover, in neuroblastoma cell lines,
this protein appears to be expressed exclusively in
highly mobile and invasive cells (23).
Another protein that affects neuronal migration dur-
ing development, even if through a totally different
mechanism, is Reelin, a high-molecular-weight secreted
glycoprotein, which is thought to play its role as a guide
for migratory neurons via the interaction with two cell
surface receptors, the very low density lipoprotein
receptor (VLDLR) and the apolipoprotein E receptor 2
(ApoER2), then triggering a tyrosine kinase signaling
cascade (24). However, the expression of this protein is
not restricted to the CNS, as it has been found in some
adult peripheral tissues and tumors. For example,
Reelin has been shown to be a positive marker for
prostate carcinoma aggressiveness (25) and is overex-
pressed in retinoblastoma (26) and esophageal carci-
noma (27).
In the present study, we sought to investigate
whether miR-128 expression is modulated in neuroblas-
toma, and whether its expression can be associated with
different features contributing to the aggressiveness of
this tumor, possibly through modulation of genes af-
fecting neuroblastoma cell motility, such as DCX and
Reelin. To this aim, we measured miR-128 expression
after in vitro ATRA treatment of SH-SY5Y neuroblas-
toma cells, and we also evaluated the expression of the
two predicted targets Reelin and DCX, in search of a
possible inverse correlation with miR-128 expression.
MiR-128 ectopic overexpression and knockdown stud-
ies were also performed, in order to unequivocally
assign the observed DCX and Reelin protein variations
solely to miR-128 expression and to correlate them with
the general inhibitory effect exerted by miR-128 on
SH-SY5Y neuroblastoma cell growth, migration, and
invasive potential. Finally, we measured the expression
levels of miR-128 in neuroblastoma samples obtained at
diagnosis from patients with locoregional vs. metastatic
disease, in search of a possible clinical significance of
miR-128 dosage in neuroblastoma.
MATERIALS AND METHODS
Cell lines and transfections
SH-SY5Y and HEK293 were maintained in DMEM supple-
mented with 10% heat-inactivated fetal bovine serum, 20 mM
l-glutamine, 100 U/ml of penicillin G sodium, and 100
g/ml streptomycin sulfate in a humidified atmosphere
containing 5% CO2 at 37°C. Transfections were performed by
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA)
in Opti-MEM I (Invitrogen), as recommended by the manu-
facturer, and stable transfectants were selected by adding 0.6
mg/ml G418 to the culture medium.
Treatment with retinoic acid (RA)
All-trans RA (ATRA; Sigma, St. Louis, MO, USA) was added to
a final concentration of 10 M. SH-SY5Y cells were plated at
a density of 1  106 cells/10-cm-diameter Petri dish and
grown in MEM supplemented as described above. For each
experiment, ATRA was diluted at the desired concentration
directly into the growth medium. The 10 M ATRA treatment
started on the second day after plating, concomitantly with
the medium replacement. Cells were fed every 48 h with
control, or ATRA-containing fresh medium, and the treat-
ment was stopped 6 d after the first addition of ATRA.
Neurite outgrowth assay
For each treatment, phase-contrast microscopic images were
acquired from 3 wells, and the total numbers of cells and the
numbers of neurites were counted in 5 randomly chosen
fields. A neurite was defined as a process 1 cell body
(average diameter of cell bodies of control cells at d 0) in
length extending from the cell (28). Acquired images were
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analyzed by ImageJ software (National Institutes of Health,
Bethesda, MD, USA), and the mean  sd values of neurite
length were determined for each treatment.
MiR-128 knockdown
The antisense LNA oligonucleotide against miR-128, and a
negative control oligonucleotide, were obtained from Am-
bion (Austin, TX, USA). Knockdown oligos were transfected
by siPORT NeoFX (Ambion) into SH-SY5Y cells (1.4106
cells/10-cm-diameter Petri dish) at a final concentration of 40
nM. A FAM-labeled negative control LNA oligonucleotide
(AM 17012; Ambion) was transfected in the same conditions
as those used for the unlabeled LNA molecule and used for
measuring transfection efficiency by fluorescence microscopy
at 24 h after transfection. Transfection efficiency was esti-
mated as 90%. The day following transfection, medium was
changed to all samples, and replaced with 10 M ATRA-
containing medium or mock medium. From this time point
on, the ATRA treatment was performed as described above,
and it was stopped 6 d after the first addition of ATRA, when
the cells were lysed for total protein and RNA extraction (for
details, see below).
Plasmid constructs
The miR-128 sequence was amplified by PCR from genomic
human DNA using the following primers: sense, 5-GAA-
GATCTTAATGGCCTTGTTCCTG-3; antisense, 5-CCGCTC-
GAGGTGGAAACCTGAGTAAAA-3. The correct sequences
of amplified products were verified by sequencing and cloned
between the KpnI and XhoI sites of pCDNA()3.1 vector (In-
vitrogen), deprived of its polyadenylation sequence, to obtain
DpA-miR-128. We chose to excise the polyadenylation signal
from the original vector, as we had previously observed that its
presence impaired miR-128 expression (data not shown).
We used pRL-TK plasmid (coding for Renilla luciferase; Pro-
mega, Madison, WI, USA) to construct the miR-128 target site
reporters, and the pGL3 plasmid (coding for Firefly luciferase;
Promega) as a control to normalize the transfection efficiency.
DNA oligonucleotides containing both target sequences for miR-
128 identified in the 3UTR of Reelin and DCX mRNAs were
purchased as single-strand molecules. Their sequences were reelin
wild-type sense, 5-CTAGTACTTTCCCACACTGTGAACTAAGA-
CAATAAGAGTTTTTTCATTGTGTTTTCTTCTCTAGAGC-3;
reelin wild type antisense, 5-GGCCGCTCTAGAGA-
AGAAAACACAATGAAAAAACTCTTATTGTCTTAG-
TTCACAGTGTGGGAAAGTA-3; reelin mutated sense,
5-CTAGTCATTTCCCAAGTGTCACACTAAGACAATAAG-
AGTTTTTTTGTGTCACTTTCTTCTCTAGAGC-3; reelin
mutated antisense, 5-GGCCGCTCTAGAGAAGAAAGTGA-
CACAAAAAAACTCTTATTGTCTTAGTGTGACACTTGG-
GAAATGA-3. DCX wild type sense, 5-CTAGTCTGAAA-
ACACTGTGAGAATTTGGACAATAAGAGCTGTGAACTG-
TGAGTGCTGAATCTAGAGC-3; DCX wild type antisense,
5-GGCCGCTCTAGATTCAGCACTCACAGTTCACAGCT-
CTTATTGTCCAAATTCTCACAGTGTTTTCAGA-3; DCX
mutated sense, 5-CTAGTCTGAAAAAGTGTCACGAATT-
TGGACAATAAGAGCTGTGAGTCACTAGTGCTGAATC-
TAGAGC-3; DCX mutated antisense, 5-GGCCGCTCT-
A G A T T C A G C A C T A G T G A C T C A C A G C T C T T A T T -
GTCCAAATTCGTGACACTTTTTCAGA-3. Oligonucleo-
tides were annealed and the double-strand products were
inserted into pRL-TK vector in a tandem duplicate (resulting
in 2 copies of each of the 2 predicted sites) between the XbaI
and NotI sites, immediately downstream of the Renilla lucif-
erase stop codon. All plasmid constructs were verified by
sequencing.
Cell viability assay
Cell viability was measured by using Promega’s Cell Titer
Aqueous assay with MTS tetrazolium, in which viable cells
convert MTS tetrazolium into a formazan-colored product
(OD
490 nm
). Cells (3000/well) were seeded in a 96-well plate.
The cell growth was then measured 48 and 96 h after cell
adhesion, following the manufacturer’s instructions.
RNA extraction and Northern blot analysis
Total RNA was extracted from SH-SY5Y cells with TRIzol
reagent (Invitrogen), according to the manufacturer’s in-
structions. For Northern blot analysis of miRNAs, 20 g of
total RNA were separated on 10% denaturing polyacrylamide
gels and electrotransferred to Immobilon Nylon membrane
(Millipore Corp., Bedford, MA, USA). The specific probes,
end-labeled by T4 polynucleotide kinase in the presence of
(-32P)ATP, were miR-128, 5-AAAAGAGACCGGTTCACT-
GTGA-3; and U6, 5-CACGAATTTGCGTGTCATCCTTGCG-
CAGGGGCC-3. Bands were quantified with ImageJ 1.34s or
OptiQuant 3.1 software (Packard Instruments, Meriden, CT, USA).
Reverse transcription and real-time PCR
For Reelin and DCX mRNA detection, 1 g of total RNA,
previously treated with DNase (Sigma), was retrotranscribed
using the High Capacity cDNA Archive Kit (Applied Biosys-
tems, Applera Italia, Monza, Italy).
Real-time PCR was performed using 1 l of cDNA and iTaq
SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA,
USA) in an ABI Prism 7000 Sequence Detection System
(Applied Biosystems), and amplifications were performed in
triplicate and repeated twice. Changes in DCX and reelin
mRNA amounts were quantified by using the Ct method
for relative quantitation of gene expression (29, 30).
Primer sequences were as follows: GAPDH-1-F 5-
GAAGGTGAAGGTCGGAGTC-3; GAPDH-2-R 5-TTGATGGCAA-
CAATATCCACTT-3; DCXH-8-F 5-CCTCAGGGAGTGCGTTA-
CAT-3; DCXH-9-R 5-ATAGCTTTCCCCTTCCTCCA-3; REL-1-F
5-CATTGGAGGTTCCAGTGCTT-3; REL-2-R 5-TCACGT-
GAGAGGCTACCACA-3.
For the detection of mature miR-128, reverse-transcriptase
reactions contained 50 ng of total RNA that was reverse
transcribed using the High Capacity cDNA Archive Kit (Ap-
plied Biosystems).
Real-Time PCR was performed using a miRNA-specific
Taq-Man Assay (Applied Biosystems) in an Applied Biosys-
tems 7900HT Sequence Detection System. U6 snRNA was
used for normalization.
Protein gel electrophoresis and immunoblotting
Cells were lysed with modified RIPA buffer (50 mM Tris-HCl,
pH 7.4; 150 mM NaCl; 0.1% Tryton X-100; 0.25% Na-
deoxycholate; 0.1 M EDTA; and 1% SDS) containing protease
(ABESF, leupeptin, and pepstatin) and phosphatase inhibi-
tors (1 mM NaF and 1 mM Na3VO4). Proteins (50–70 g)
were separated on SDS-12% (10% for Gap43) PAGE under
reducing conditions and transferred onto nitrocellulose
membranes. Primary antibodies used were the following: anti-
DCX (C-18 sc-8066; 1:500) and anti-LIS1 (H-300 sc-15319; 1:200)
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA); anti-
vimentin (1:10,000), anti-Gap43 (clone GAP-7B10, 1:4000), anti-
actin (1:1000), and anti-	-tubulin (1:500) from Sigma. The second-
ary antibodies used were HRP-conjugated anti-goat (for anti-DCX
antibody), anti-rabbit (for anti-LIS1), and anti-mouse (for anti-	-
tubulin, anti-
-actin, anti-Gap43, and anti-vimentin antibody) from
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Santa Cruz Biotechnologies. Detection and visualization of protein-
bound antibodies was achieved using an enhanced chemilumines-
cence WB detection kit (ECL Plus; Amersham Biosciences, Piscat-
away, NJ, USA). To quantify the intensity of the bands, membranes
were scanned and analyzed with the ImageJ software.
For the miR-128 knockdown experiment, we wanted to
visualize both DCX and Reelin in the same intracellular
protein extracts, in order to be able to compare directly these
two proteins and the endogenous control protein, 
-tubulin.
To this aim, 70 g of proteins was separated onto a 3–8%
NuPAGE Novex precast gradient gel (Invitrogen) and trans-
ferred onto nitrocellulose membranes. Primary and second-
ary antibodies for DCX and 
-tubulin detection were the
same as described above, and for Reelin detection mAb 142
(MAB5366; Chemicon, Temecula, CA, USA) was employed as
the primary antibody, with a secondary horseradish peroxi-
dase-conjugated antibody (AP160P; Chemicon).
For analyzing Reelin secretion into supernatants, cells were
plated onto 60-mm dishes and grown for 24 h; then cells were
washed twice with PBS, and serum-free medium was added
and kept for the following 24 h, after which the supernatants
were collected, cleared by a brief centrifugation at 4°C,
concentrated 30 times by Centricon Plus-20 (Millipore),
and stored at 80°C. Concentrated supernatants were sepa-
rated on 6% SDS-PAGE gels and transferred to nitrocellulose
membrane. Western blot was performed by using mAb 142
(MAB5366; Chemicon). The secondary horseradish peroxi-
dase-conjugated antibody (AP160P; Chemicon) was detected
using ECL Plus Western blotting detection reagents (Amer-
sham Biosciences). Bands were quantified with ImageJ 1.34 or
OptiQuant 3.1. Ponceau staining of the blots was used to
normalize immunoreactive Reelin signal, as no secreted en-
dogenous control of a comparable molecular weight is avail-
able, to our knowledge, for normalization.
Assay of luciferase activity
HEK293 cells were seeded in 24-well plates 24 h before
transfection. Cells were cotransfected with 1 g of DpA-miR-
128 (miR-128) or empty vector (DpA), 50 ng of target reporter
(wild-type or mutated), and 5 ng of pGL3 control in the
presence of Lipofectamine2000 reagent (Invitrogen). Forty-
eight hours after transfection, the luciferase activity was
determined using the dual-luciferase assay system (Promega),
according to the manufacturer’s instructions. The Renilla
luciferase activity was normalized by dividing by the Firefly
luciferase activity of the same transfection, and the normal-
ized luciferase activity in empty vector transfection was set to
1.0 as a reference.
DCX immunofluorescence analysis
Cells were grown on 13-mm-diameter coverslips, fixed in 4%
paraformaldehyde (PFA), and permeabilized in 0.2% Triton
X-100, and the unspecific sites were blocked in 10% normal
donkey serum (Sigma) in PBS. Subsequently, cells were
incubated with the primary antibody (anti-DCX, C-18 sc-8066;
1:500; Santa Cruz Biotechnology) for 1 h at room tempera-
ture and then rinsed with PBS. As a secondary antibody,
Cy3-conjugated anti-goat (Jackson ImmunoResearch, West
Grove, PA, USA) was used (1 h at room temperature). Nuclei
were stained with DAPI (Sigma-Aldrich). Finally, the cells
were washed in PBS before mounting using Mowiol 40–88
(Sigma-Aldrich).
Wound-scratch assay
To investigate cell migration capability, a modified wound-
scratch assay was used (31, 32). Briefly, cells were grown to
confluent monolayers, and when approaching 100% cell
confluence, the monolayers were wounded by scratching the
surface as uniformly as possible with a pipette tip. This initial
wounding and the movement of the cells in the scratched
area was photographically monitored using the Axiovert Zeiss
200 microscope (Carl Zeiss, Oberkochen, Germany) with an
10 (NA 0.25) objective linked to a Coolsnap Es charge-
coupled device camera (Roper Scientific-Crisel Instruments,
Rome, Italy) for 24 h. The migration rate is expressed as a
percentage of the control, and it was calculated as the
proportion of the mean distance between both borderlines
caused by scratching, to the distance that remained cell-free
after regrowing (31). Two independent series of experiments
were performed in quadruplicate.
Cell invasion assay
Cell invasion was determined by a modified microchemotaxis
assay (33) using cell culture 24-well inserts with the bottom
sealed by an 8-m-pore polycarbonate filter coated with
Matrigel (Chemicon). Briefly, 2.5  105 cells in 250 l of
serum-free MEM were seeded into the inserts. Chambers were
incubated at 37°C in a 5% CO2 atmosphere for 48 h. The cells
migrated to the underside of the coated filter were incubated
with cell-detachment buffer and dissociated from the filter.
The cells were then lysed and stained by CyQuant GR dye.
Fluorescence was counted using Victor3 multilabel readers
(PerkinElmer, Wellesley, MA, USA). Data are expressed as
means  se; n  4.
Image acquisition
Images were acquired using the UIC-Metavue 6.2.2 (UIC-
Crisel Instruments) imaging system on an Axiovert Zeiss 200
microscope. An oil immersion 63 (NA 1.4) or a 40 (NA
0.8) objective was used for IF images.
For the wound scratch test analysis, images were acquired
using a 10 (NA 0.25) objective. The distance between the
borderlines of the scratched area was measured using the
Region Measurement Function included in UIC-Metavue 6.2.2.
Tissue collection
Tumor samples from primary site were obtained by surgery
from 28 children with newly diagnosed neuroblastoma admit-
ted to the Department of Pediatrics at Sapienza University
and to the Division of Oncology at Royal Liverpool Children’s
National Health Service Trust Alder Hey. No selection criteria
were applied except for the availability of adequate tumor
tissue for the analysis. Institutional written informed consent
was obtained from the patient’s parents or legal guardians.
The study underwent ethical review and approval according
to local institutional guidelines. Patients, 16 males and 12
females, were aged from 1 d to 336 mo (median, 25 mo).
Primary site was adrenal in 17 patients, abdominal nonadre-
nal in 9, and thoracic in 2. Histopathological grading was
carried out according to the International Neuroblastoma
Pathology Classification (34), and the final clinical-patholog-
ical diagnosis fulfilled the International Criteria for Neuro-
blastoma Diagnosis (35). The 28 patients were staged accord-
ing to the International Neuroblastoma Staging System (35):
9 patients were at stage 1, 2 at stage 2, 1 at stage 3, 15 at stage
4, and 1 at stage 4S. As of December 2008, the median
follow-up for the 28 patients was 53 mo (range: 1 to 147). In
16 disease-free (DF) patients, a median follow-up of 95 mo
(range 48 to 147) was observed. In the remaining 12 patients,
either dead of complications (DOC, n 1) or dead of disease
(DOD, n  11), a median follow-up of 9 mo (range 1 to 44)
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was recorded. All clinicopathological features of the patients
are included in Supplemental Table 1.
Statistical analysis
Results of quantitative analysis of in vitro experiments are
presented as means  se or sd, as specified in the figure
legends. Control and treated samples were compared by
the 1-sided unpaired Student’s t test or by ANOVA and
using the GraphPad Prism 4.0 software (GraphPad, San
Diego, CA, USA). The results were considered statistically
significant vs. the untreated cells, with a probability level of
P  0.05, or highly statistically significant with a probability
level of P  0.001.
For patient samples, associations between miR-128 expres-
sion and clinicopathological features were evaluated using
the 2-sided Student’s t test for independent samples, with a
significance level of 0.01. Original data were previously log
transformed to stabilize the variance. To investigate on sur-
vival, the 28 patients were divided into two groups with “low”
and “high” expression using the miR-128 median value of
0.749 as cutoff point, and survival curves were computed for
each group using the Kaplan-Meier method. The difference
between curves was assessed by log-rank test, using SPSS for
Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
MiR-128 expression is up-regulated following ATRA
treatment of neuroblastoma cells
On the basis of both in vitro and in vivo data, it is widely
recognized that the degree of differentiation of neuro-
blastoma cells is a good predictor of patient outcome.
The availability of chemical agents that are able to
induce the in vitro differentiation of human neuroblas-
toma cell lines has highlighted neuroblastoma cell lines
as a very interesting model of differentiation, as op-
posed to tumor growth. In SH-SY5Y cells, ATRA treat-
ment is able to inhibit cell growth potential, inducing
clear morphological changes, such as the protrusion of
neuritic extensions.
To test whether the expression of miR-128, a neuron-
specific microRNA, is somehow modulated during
ATRA treatment of SH-SY5Y cells, we treated these cells
with 10 M ATRA for 6 d. We assessed this treatment
and found that it reproducibly induced morphological
differentiation of SH-SY5Y cells (Fig. 1A), as confirmed
also by the up-regulation of Gap43 (Fig. 1B), a protein
involved in neurite outgrowth (36), and we demonstrated
that miR-128 expression was up-regulated (3 fold) in
treated cells as compared to untreated ones (Fig. 1C).
The protein expression of Reelin and DCX, two
predicted targets of miR-128, is down-regulated in
ATRA-treated SH-SY5Y cells
To identify the functional significance of the observed
miR-128 induction, we performed a bioinformatic screen-
ing (Targetscan: http://www.targetscan.org/, and PicTar:
http://pictar.bio.nyu.edu/) of miR-128 predicted target
mRNAs, focusing on the two molecules specifically
involved in the migration of neuronal cells: Reelin and
DCX. The bioinformatic search for microRNAs pre-
dicted to target the mRNAs of both molecules yielded
miR-128 as the most likely candidate, highly ranked in
both cases, with two predicted sites both in Reelin and
in DCX mRNA 3UTRs. Moreover, when comparing
the human Reelin and DCX 3UTRs for interspecies
homology, we found that the miR-128 target sites are
highly conserved among 6 and 5 species, respectively
(Fig. 2A).
Figure 1. MiR-128 expression is up-regulated following neuronal
differentiation of SH-SY5Y cells with ATRA. A) Representative
images of SH-SY5Y cells differentiated by ATRA. Cells treated with
10 M ATRA display morphological changes, such as neuritic
extensions, that are indicative of a differentiated state (right
panel). Bar graph displays mean  sd neurite length in mock or
ATRA-treated cells, calculated vs. 1 average diameter of control
cells at d 0. Average number of neurites per cell is also indicated
for each treatment type. B) Western blot analysis of the expression
of the neuronal marker Gap43 performed on total cell extracts
from treated (ATRA) or control (C) SH-SY5Y cells. Actin
immunoreactivity is shown as a loading control. C) Northern
blot analysis of total RNA extracted from SH-SY5Y cells treated
with 10 M ATRA for 6 d. Hybridization to the U6 small
nuclear RNA is shown as a loading control. Graph shows relative miR-128 expression. Error bars  sd; n  4 samples.
*P  0.05 vs. control.
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To check whether an inverse correlation exists between
miR-128 expression in neuroblastoma cells and that of
miR-128 predicted targets, we analyzed the levels of Reelin
and DCX after differentiation of SH-SY5Y cells. As shown
in Fig. 2B, secreted Reelin protein levels significantly drop
in differentiated cells as compared to control cells.
We recently demonstrated that RA treatment is able to
down-regulate DCX expression in SK-N-SH neuroblas-
toma cells (23). SH-SY5Y is a cell line that was obtained by
subcloning from SK-N-SH cells and is made of an almost
homogeneous population of neuroblastic cells, widely
showing DCX immunoreactivity (Fig. 2Cb). As shown in
Fig. 2Cd, the presence of DCX-positive cells was drastically
reduced after ATRA treatment. This result was confirmed
by Western blot analysis performed on total cell lysates of
ATRA-treated cells. Fig. 2D shows that the extent of this
reduction can be estimated at 61.9 11.9%, as compared
to untreated cells.
These results led us to hypothesize that the observed
inverse relationship between miR-128 and Reelin and
DCX protein expression could be due, at least in part,
to a direct regulatory effect exerted by miR-128 on
Reelin and DCX mRNAs.
MiR-128 down-regulates Reelin and DCX protein
levels in cultured neuroblastoma cells
To have a closer view of the possible relationship
inversely linking miR-128 to DCX and Reelin, we ec-
topically overexpressed miR-128 in SH-SY5Y cells and
analyzed Reelin and DCX protein levels by Western
blot analysis. Cells were transfected with DpA-miR-128,
encoding for miR-128, or with control vector. Northern
blot analysis of SH-SY5Y cells stably transfected with
DpA-miR-128 showed high levels of the expected ma-
ture microRNA, whereas very little expression was de-
tected in control-transfected cells (Fig. 3A). Western
blot analysis showed that Reelin protein was clearly
reduced in SH-SY5Y cells expressing high levels of
miR-128, as compared with cells transfected with the
empty vector (Fig. 3B).
Figure 2. ATRA treatment lowers Reelin and DCX protein
expression in SH-SY5Y neuroblastoma cells. A) 3UTR align-
ments and location of predicted sites. Reelin and DCX
3UTR sequences are numbered starting from the first 3UTR
nucleotide. Hs, Homo sapiens; Pt, Pan troglodytes; Mm, Mus
musculus; Rn, Rattus norvegicus; Cf, Canis familiaris; Gg, Gallus
gallus. B) Effect of ATRA treatment on endogenous Reelin
levels. Western blot analysis of secreted Reelin was performed
on SH-SY5Y supernatants following 6 d of ATRA treatment. Left panel: differentiated SH-SY5Y cells show a marked
reduction in Reelin levels. Right panel: Ponceau staining of the filter as a loading control. C) Effect of ATRA treatment on
endogenous DCX levels. Phase contrast (a, c) or immmunofluorescence images (b, d) of SH-SY5Y cells before (a, b) and
after (c, d) a 6-d treatment with 10 M ATRA. After treatment, cells are morphologically differentiated, showing long
neuritic processes (c), and DCX immunoreactivity is severely reduced (d), as compared to undifferentiated cells (b). Scale
bars 50 m. D) Effect of ATRA treatment on endogenous DCX levels. Western blot analysis of DCX expression performed
on total cell extracts from treated (ATRA) or control (C) SH-SY5Y cells provides evidence of a strong reduction of DCX
expression in differentiated cells. Bar graph shows densitometric quantification of the Western blot results. Relative DCX
amounts are expressed as the ratio to tubulin expression, and represent the average  se of 6 independent experiments.
**P  0.01.
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DCX expression was also negatively affected in miR-
128-transfected SH-SY5Y cells. Fig. 3C shows the great
reduction of DCX cells in the SH-SY5Y cell line stably
transfected with DpA-miR-128. This result is more
clearly quantified by the Western blot analysis shown in
Fig. 3D. The sharp decrease of DCX protein level was
not accompanied by any perturbation of two other
cytoskeletal proteins, LIS1 and vimentin, that, as we
have already shown for other neuroblastoma cell lines,
are modulated during ATRA-induced neuroblastoma
cell differentiation (23).
Moreover, we also measured DCX mRNA levels by
Q-RT-PCR in miR-128-transfected cells, and we verified
that they were significantly reduced (75%) as com-
pared to those measured in control cells (Fig. 3E, left
panel). On the contrary, reelin mRNA levels were not
affected by miR-128 ectopic expression (Fig. 3E, right
panel).
To measure the extent to which DCX and Reelin
modulation is mediated by miR-128, we inhibited the
endogenous miR-128 in SH-SY5Y cells by transfecting
them with anti-miR-128-specific LNA antisense oligonu-
cleotides, and evaluated DCX and Reelin protein
amounts in RA-treated cells. The inhibition of miR-128
achieved in ATRA-treated cells was nearly 100% (Fig.
3F) and corresponded to a significant enhancement of
DCX and Reelin levels, returning very close to those
observed in the absence of ATRA treatment. (Fig. 3G).
The results of miR-128-overexpression and loss-of-
function experiments are complementary and suggest
that miR-128 specifically down-regulates Reelin and
DCX at the post-transcriptional level.
The Reelin and DCX 3UTRs are direct targets of
miR-128
To check the hypothesis that Reelin and DCX are
targets of miR-128, we asked whether the 3UTRs of
their mRNAs are true functional targets of miR-128. We
cloned DNA oligonucleotides containing both miR-128
target sequences identified in the 3UTR of Reelin into
pRL-TK plasmid, downstream of the luciferase reporter
gene. In parallel, we produced a second reporter
construct in which the conserved miR-128 target sites
were mutated in their seed regions. Transient cotrans-
fection of HEK293 cells, lacking endogenous miR-128
expression, with the wild-type reporter construct to-
Figure 3. Ectopic expression of miR-128 down-regulates Reelin and DCX protein levels in SH-SY5Y cells, and its LNA-mediated
depletion restores Reelin and DCX. A) Northern blot analysis of total RNA extracted from SH-SY5Y cells stably transfected with
the empty vector (DpA) or DpA-miR-128 (miR-128). Hybridization to the U6 small nuclear RNA is shown as a loading control.
B) Left panel: Western blot analysis of Reelin. Supernatants from the same SH-SY5Y cells utilized in A. Right panel: Graph
represents the quantification of the major Reelin bands in miR-128 transduced cells as compared to the empty vector (DpA)
transfected cells. Error bars  sd; 3 independent experiments. Center panel: Ponceau staining of the filter as a loading control.
C) Immunofluorescence analysis of DCX expression in control (DpA) or miR-128-transfected SH-SY5Y cells. Red, DCX; blue,
nuclei (DAPI staining). Scale bars  300 m. D) Left panel: Western blot analysis of DCX expression in DpA- or
DpA-miR-128-transfected cells. Experiments also show that LIS1 and vimentin (VIM) are not affected by miR-128 ectopical
expression. Right panel: Bar graph represents densitometric quantification of DCX vs. tubulin. Data are expressed as the
average se of 6 independent experiments. E) Real-time RT-PCR analysis of DCX (left panel) or reelin (right panel) expression
in DpA- or DpA-miR-128-transfected cells. Data are expressed as the average  sd of 2 independent experiments performed in
triplicate. F) Northern blot analysis of miR-128 expression in SH-SY5Y cells transfected with an anti-miR-128 LNA antisense
oligonucleotide and treated with 10 M ATRA for 6 d. Lane 1: mock-transfected cells; lane 2: cells transfected with negative
control LNA oligonucleotide (NC); lane 3: cells transfected with anti-128 antisense LNA oligonucleotide (	128). Hybridization
to the U6 small nuclear RNA is shown as a loading control. G) Western blot analysis of DCX and Reelin expression in SH-SY5Y
cells transfected with an anti-miR-128 LNA antisense oligonucleotide, and treated with 10 M ATRA for 6 d. Lanes 1–3
correspond to total protein extracts from untreated cells (C); lanes 4–6 to protein extracts from ATRA-treated cells (ATRA).
Lanes 1 and 4: mock-transfected cells; lanes 2 and 5: cells transfected with negative control LNA oligonucleotide; lanes 3 and
6: cells transfected with anti-128 antisense LNA oligonucleotide. Tubulin immunoreactivity is shown as a loading control. *P
0.05; **P  0.001.
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gether with plasmid DpA-miR-128 led to a significant
decrease of luciferase activity (40%) as compared to
the control (Fig. 4A). However, the activity of the
reporter construct mutated at the specific miR-128
target sites was unaffected by the concomitant transfec-
tion of DpA-miR-128. Analogous results were obtained
when we cloned the miR-128 predicted binding sites of
DCX 3UTR in the same pRL-TK-based construct: the
presence of the wild-type sites was sufficient to signifi-
cantly decrease luciferase activity (57%), while the
mutated sites were inactive (Fig. 4B).Thus, the two
miR-128 target sites predicted in the Reelin and DCX
3UTRs are sufficient and necessary to induce the
miR-128-mediated decrease of the corresponding pro-
tein products.
MiR-128 decreases SH-SY5Y neuroblastoma cell
growth and motility
A key characteristic of tumor cells, highly related to
their relative degree of aggressiveness, is their ability to
migrate and eventually disseminate to distal sites. We
aimed to check whether ectopic miR-128 expression is
able to affect this aspect of neuroblastoma biology.
To visualize the possible involvement of miR-128
expression in modulating SH-SY5Y cell motility, we
used a wound-healing assay in cells stably transfected
with DpA-miR-128 or with a control vector. The
transfected cells were monitored for 24 h, starting
immediately after the initial wounding. As shown in
Fig. 5C, 24 h after the scratch, control cells had
almost fully recolonized the scratched area, while at
the same time point, miR-128-expressing cells had
only slightly moved into the area, and the distance
between the borders of the wound was not signifi-
cantly different from that measured immediately
after scratching (Fig. 5B). Thus, the overexpression
of miR-128 produced 46.3% reduction of cell migra-
tion rate with respect to SH-SY5Y cells transfected
with the empty vector (Fig. 5A).
We also tested whether the overexpression of miR-
128 affects cell growth. Viability of DpA-miR-128 or
control vector transiently transfected SH-SY5Y cells was
determined by MTS assays. As clearly depicted in Fig.
5D, cells expressing ectopic miR-128 were significantly
delayed in their growth, as compared to control cells
(30% at 48 h, 22% at 96 h).
MiR-128 down-regulates neuroblastoma cell
invasiveness
To determine whether overexpression of miR-128 af-
fects invasiveness of neuroblastoma cells, we carried out
in vitro matrigel invasion assay, which is a reliable test to
evaluate cancer cell invasiveness reflecting the ability of
cancer cells to invade and metastasize in vivo. We used
SH-SY5Y cells stably transfected with DpA-miR-128 or
control vector. Cells were plated in a transwell Boyden
chamber, and 48 h later, invasive cells on the bottom
side of the membrane were dislodged and stained with
a fluorescent dye. Fluorescence was counted using a
multilabel reader. Data show that overexpression of
miR-128 reduced the invasion of DpA-miR-128-trans-
fected cells (Fig. 5E).
Analysis of miR-128 expression in human primary
neuroblastomas
To test whether alterations of miR-128 expression
might also be relevant in neuroblastic carcinogenesis in
vivo, its expression was measured by Q-RT-PCR in a
small set of untreated primary neuroblastoma tumors.
The levels of miR-128 expression varied considerably in
the different samples (Supplemental Fig. 1). There-
fore, we considered whether different levels of miR-128
expression were associated with any particular clinico-
pathological features. We noticed a general trend for
higher levels of expression to be associated with favorable
features, such as early age at diagnosis, favorable Shimada
Figure 4. Reelin and DCX 3UTRs are targets of miR-128.
Luciferase reporter assays showing the regulatory action of
miR-128 on Reelin (A) and DCX (B) 3UTR sites. Reporter
constructs containing wild-type or mutated DNA oligonucle-
otides representing target sequences for miR-128 from Reelin
(A) or DCX (B) 3UTRs were cotransfected into HEK293 cells
with empty vector (DpA; white bars), or DpA-miR-128 (miR-
128; gray bars). Luciferase activity was determined 48 h after
transfection. Values represent means  sd of 6 independent
transfections. **P  0.001. Center panel: Northern blot
showing miR-128 expression in HEK293 cells transfected with
empty vector (DpA) or DpA-miR-128 (miR-128). Hybridiza-
tion to the U6 small nuclear RNA is shown as a loading
control.
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category, prognostically favorable stages (stages 1, 2, 3,
and 4S), and MYCN single-copy status (Fig. 6). Although
some associations individually reached statistical signif-
icance (not shown), these data need to be confirmed in
a larger series of primary neuroblastomas. Nevertheless,
they suggest that the miR-128 expression and functions
that we characterized in neuroblastoma cell lines might
also have an impact on the in vivo tumor behavior.
Figure 5. MiR-128 reduces the mo-
tility, growth, and invasiveness of
SH-SY5Y neuroblastoma cells. A–C)
Overexpression of miR-128 re-
duces cell migration rate with re-
spect to the experimental control,
consisting of empty-vector (DpA)
transfection in a wound-healing
assay on SH-SY5Y cells. Four differ-
ent fields from each sample were
considered for quantitative esti-
mation of the distance between
the borderlines; in each image, 4
different equidistant points were
measured in order to better esti-
mate the real width of the
wounded area. A) Bars represent
migration rate, expressed as a per-
centage of control and calculated
as the proportion of the mean distance between both borderlines caused by scratching to the distance that remained
cell-free after regrowing. Data are expressed as the average  se of 6 independent experiments. B) Bars represent scratch
width measure. Data are averages  se of 6 experiments. C) Representative images of the miR-128-induced reduction of
SH-SY5Y cell migration in a wound-healing assay. Pictures were taken immediately after scratching the cultures (t 0 h) and
24 h later (t 24 h). This time interval was chosen because it is shorter than the SH-SY5Y cell doubling time. Scale bars 
200 m. D) MiR-128 expression reduces cell growth. SH-SY5Y cells were transfected with either DpA control vector (DpA)
or DpA-miR-128 (miR-128). Cell viability was determined at the indicated times after transfection by MTS assay. Values are
averages  sd of 3 independent experiments. E) MiR-128 expression reduces cell invasiveness. Neuroblastoma cells
transfected with either DpA control vector (DpA) or DpA-miR-128 (miR-128) were plated in matrigel invasion chambers
and treated. After 48 h incubation at 37°C, cells on the top surface of the chamber were gently removed. Invasive cells on
the bottom of the membrane were detached and stained with a fluorescent dye. Fluorescence was counted using a
multilabel reader. Data represent means  se of 4 experiments. RFU, relative fluorescence units. *P  0.05, **P  0.001vs.
control.
Figure 6. MiR-128 expression and clinical-pathological features in a series of 28 primary human neuroblastomas. Box-plot
representation of miR-128 expression (as measured by Q-RT-PCR; see Supplemental Fig. 1) in NB primary samples stratified
according to different clinical-pathological features. UF, unfavorable; F, favorable. One of the samples was undetermined for
MYCN copy number and did not enter the analysis.
4284 Vol. 23 December 2009 EVANGELISTI ET AL.The FASEB Journal  www.fasebj.org
DISCUSSION
In this report we describe for the first time the role of
a neuronal enriched microRNA, miR-128, in the mo-
lecular changes taking place in neuroblastoma cells. A
key result of our work is that we identified two targets of
miR-128 action, Reelin and DCX, which are both
involved in the migratory potential of neuronal cells,
although via distinct mechanisms. It is noteworthy that
the expression of miR-128 was significantly up-regu-
lated following the induction of differentiation in SH-
SY5Y neuroblastoma cells. A specific activation of miR-
128 was previously described in analogous models of in
vitro RA-induced differentiation of mouse P19 and
human NTera-2/D1 cells (37) and was also detected by
high throughput methods in SH-SY5Y cells, as well as in
NT2 teratocarcinoma cells, treated with RA (38). Con-
versely, we have previously shown that miR-128 is the
most down-regulated microRNA in GBM tumors and
cell lines (10), and Mi et al. (39) showed that miR-128
is one of the most discriminatory microRNAs, clearly
distinguishing acute lymphoblastic leukemia (ALL)
from acute myeloid leukemia (AML). MiR-128 is
strongly overexpressed in ALL, generally characterized
by a better prognosis than AML. However, these obser-
vations have never gone beyond a mere description of
miR-128 modulation, without further in-depth clarifica-
tion of the biological meaning of miR-128 variant
expression. Here, we have not only correlated miR-128
expression with the ability of neuroblastoma cells to
proliferate and migrate through an extracellular matrix
but have also identified two of the molecules through
which miR-128 exerts its function. DCX has recently
been described as a marker of SK-N-SH neuroblastoma
cells that show high motility and invasiveness (23), and
its expression in those cells has consistently been shown
to be reduced by RA treatment. Our present data,
besides confirming the down-modulation of DCX ex-
pression in response to RA in another neuroblastoma
cell line, provide a first hint about the mechanism
through which RA may work to reduce DCX and thus
cell migration. To our knowledge, this is the first time
that the modulation of Reelin protein expression is
described in the context of neuroblastoma cell differ-
entiation. In 2007, a study from Chen et al. (40)
reported apparently conflicting results with regard to
the positive regulation of the Reelin promoter after
ATRA treatment. Nonetheless, the experimental condi-
tions described in that report were significantly differ-
ent from ours, mostly because in that case, the cells
treated with ATRA were neuronal precursor cells, NT-2,
which are very different from a tumor cell line such as
SH-SY5Y. Also, Reelin protein level was not quantitated
in that context (40).
In general, no studies have been performed that link
Reelin and neuroblastoma, while it is already known
that this protein is modulated in other cancer types
(25–27, 41) in the majority of which, Reelin expression
is directly correlated with tumor aggressiveness (25–
27). The present findings support the existence of
another mechanism through which miR-128 reduces
neuroblastoma cell motility and invasiveness, i.e., by
reducing Reelin protein levels. This, in turn, confirms
miR-128 as one of the mediators of RA action in
neuroblastoma cells. A recent paper by Chen and
Stallings (42) reported that 32 microRNAs are differ-
entially expressed in distinct subtypes of primary neu-
roblastomas and compared the expression of these
microRNAs in neuroblastoma SK-N-BE cells exposed to
5 M ATRA for 5 d. In that in vitro system, the authors
did not detect any variation of miR-128. However, this
does not conflict with our findings, as Chen and
Stallings did not study miR-128 but limited the analysis to
the most significant microRNAs they detected in tumor
samples and focused on MYCN-amplified (MNA) tumors
vs. non-MNA tumors specifically studying the relationship
between MYC, ATRA treatment, and microRNAs.
Our results, inversely linking miR-128 on one hand
and Reelin and DCX on the other, are interesting as
they provide further evidence of a “pleiotropic” way of
action typical of microRNAs: one single microRNA
yields a functional result (i.e., reduction of cell migra-
tion) by interfering with the production of multiple
proteins, each of which is individually involved in the
process that is being regulated. In fact, while DCX is a
microtubule-associated protein that works as a modula-
tor of neuroblastic migration via a totally intracellular
pathway, Reelin is a secreted protein whose mechanism
of action involves the binding to extracellular recep-
tors. The multifaceted action of microRNAs is further
confirmed in our work by the observation that miR-128
can reduce DCX mRNA levels, whereas it does not
affect reelin mRNA amount. This is not an uncommon
finding, as microRNAs are known to choose distinct
ways of modulating distinct targets, even if the molec-
ular basis of the different behaviors is still far from
being explained. Some features can be recognized that
actually distinguish reelin 3UTR from DCX one. Both
DCX and reelin mature mRNAs are very long mole-
cules, but they are composed in two somehow comple-
mentary ways: a very long coding sequence followed by
a relatively short 3UTR for reelin (10,4001028 nt),
and a short coding sequence followed by a huge 3UTR
for DCX (13007908 nt). The large extension of the
latter 3UTR suggests a robust role for it in DCX mRNA
stability. In any case, while the two miR-128 target sites
in each mRNA are identical in their seed complemen-
tary sequences, they largely differ in the surrounding
nucleotides. This likely contributes to the different
effects of miR-128 onto reelin and DCX mRNAs.
MiR-128 pleiotropism can be relevant both for differ-
entiation and tumor progression. Migration and, even
more, invasion are a necessary requisite in neuronal
maturation, but they are equally important in the acqui-
sition of a critical tumor feature such as the ability to
metastasize. While this manuscript was in preparation,
Zhang et al. (43) demonstrated that miR-128 targets the
transcription factor E2F3a in glioma cells, thus reduc-
ing their proliferation rate. On the basis of these
findings, the study of the miR-128-E2F3a regulatory link
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deserves further study also in neuroblastoma. We have
also shown that undifferentiated neuroblastoma cells
do not express miR-128 but are able to activate expres-
sion when treated with RA. In addition, when miR-128
is forcedly expressed in untreated cells, it is sufficient by
itself to produce some functional results typically in-
duced by RA, such as the inhibition of proliferation,
migration, and invasiveness. We can speculate that
during the development of neuroblastoma, loss of
miR-128 expression can occur in concomitance with an
increase of aggressiveness and distant spread. Although
our analysis of a small subset of primary neuroblasto-
mas does not allow us to draw any definite conclusion,
yet it provides some preliminary evidence for a reduced
expression of miR-128 in stage 4 tumors as compared to
locoregional neuroblastomas. More, in general, we
found that higher miR-128 expression levels are associ-
ated with favorable clinicobiological features, such as
very early age at diagnosis and favorable Shimada
category. Whether confirmed in a larger series of
primary neuroblastomas, these data would imply that
the miR-128 activities we characterized in neuroblas-
toma cell lines might also impact on the in vivo tumor
behavior. Consistent with this hypothesis is the obser-
vation that one of the two copies of miR-128, miR-128-2,
is encoded by a gene located on chromosome 3p22.3, a
region whose loss has been associated with the most
aggressive forms of neuroblastoma (44, 45). To date,
no tumor suppressor gene mapping to this region has
been identified, leaving open the possibility that miR-
128-2 may be the relevant element lost at 3p22.3.
Because of the very limited amount of material, we
were unable to address whether DCX and Reelin pro-
tein expression significantly varied in primary tumors
with high miR-128 expression. As it could be expected
because of the large number of variables affecting
mRNA expression, a Q-RT-PCR analysis of our small
subset of primary tumors showed only marginally a
correlation between miR-128 and DCX mRNA levels
(not shown). Nevertheless, DCX expression was sug-
gested as a reliable marker for the detection of disease
dissemination and minimal residual disease in neuro-
blastoma (22), suggesting that the possibility of an
association between miR-128, DCX, and neuroblastoma
in vivo aggressiveness needs to be thoroughly ad-
dressed. Presently, no data are available regarding
Reelin expression and neuroblastoma aggressiveness.
These subjects, together with the enticing hypothesis
that loss or reduction of miR-128 can be considered a
marker of high-risk neuroblastoma, deserves further
investigations.
CONCLUSIONS
We have demonstrated a new role of miR-128 in
neuroblastoma as a modulator of Reelin and DCX. This
underpins future studies aimed at defining whether a
role as true tumor suppressor can be conferred to
miR-128 and whether its expression levels can be ex-
ploited as a new tool for categorizing risk class in this
disease.
The authors are grateful to Dr. Pierluigi Altavista (Section
of Toxicology and Biomedical Sciences, ENEA Research
Center Casaccia, Rome) for performing the statistical analy-
sis. This study was funded in part by grants from the Italian
Ministry of Instruction, University and Scientific Research,
FIRB RBNE01H3K5 to S.A.C., FIRB RBNE01MBEC and Italy-
USA Collaborative Programme, Ministry of Health to MGF,
and from Associazione Italiana per la Ricerca sul Cancro,
Ministry of Health, the National Research Council, the Min-
istry of University and Research, Telethon grant GGP07118
to G.G.
REFERENCES
1. Kato, M., and Slack, F. J. (2008) microRNAs: small molecules
with big roles—C. elegans to human cancer. Biol. Cell 100, 71–81
2. Filipowicz, W., Bhattacharyya, S. N., and Sonenberg, N. (2008)
Mechanisms of post-transcriptional regulation by microRNAs:
are the answers in sight? Nat. Rev. Genet. 9, 102–114
3. Eulalio, A., Huntzinger, E., and Izaurralde, E. (2008) Getting to
the root of miRNA-mediated gene silencing. Cell 132, 9–14
4. Watanabe, Y., Tomita, M., and Kanai, A. (2007) Computational
methods for MicroRNA target prediction. Methods Enzymol. 427,
65–86
5. Bartel, D. P. (2004) MicroRNAs: Genomics, biogenesis, mecha-
nism, and function. Cell 116, 281–297
6. Doench, J. G., and Sharp, P. A. (2004) Specificity of microRNA
target selection in translational repression. Genes Dev. 18, 504–
511
7. Gao, F. B. (2008) Posttranscriptional control of neuronal devel-
opment by microRNA networks. Trends Neurosci. 31, 20–26
8. Lee, R. C., Feinbaum, R. L., and Ambros, V. (1993) The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell 75, 843–854
9. Reinhart, B. J., Slack, F. J., Basson, M., Pasquinelli, A. E.,
Bettinger, J. C., Rougvie, A. E., Horvitz, H. R., and Ruvkun, G.
(2000) The 21-nucleotide let-7 RNA regulates developmental
timing in Caenorhabditis elegans. Nature 403, 901–906
10. Ciafre`, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G.,
Sabatino, G., Negrini, M., Maira, G., Croce, C. M., and Farace,
M. G. (2005) Extensive modulation of a set of microRNAs in
primary glioblastoma. Biochem. Biophys. Res. Commun. 334, 1351–
1358
11. Maris, J. M., Hogarty, M. D., Bagatell, R., and Cohn, S. L. (2007)
Neuroblastoma. Lancet 369, 2106–2120
12. Castel, V., Grau, E., Noguera, R., and Martinez, F. (2007)
Molecular biology of neuroblastoma. Clin. Transl. Oncol. 9,
478–483
13. De Bernardi, B., Nicolas, B., Boni, L., Indolfi, P., Carli, M.,
Cordero di Montezemolo, L., Donfrancesco, A., Pession, A.,
Provenni, M., di Cataldo, A., Rizzo, A., Tonini, G. P., Dall’orso,
S., Conte, M., Gambini, C., Garaventa, A., Sonetti, F., Zanazzo,
A., D’Angelo, P., and Bruzzi, P. (2003) Disseminated neuroblas-
toma in children older than one year at diagnosis: comparable
results with three consecutive high-dose protocols adopted by
the Italian Co-Operative Group for Neuroblastoma. J. Clin.
Oncol. 21, 1592–1601
14. Des Portes, V., Pinard, J. M., Billuart, P., Vinet, M. C., Koulakoff,
A., Carrie, A., Gelot, A., Dupuis, E., Motte, J., Berwald-Netter, Y.,
Catala, M., Kahn, A., Beldjord, C., and Chelly, J. (1998) A novel
CNS gene required for neuronal migration and involved in
X-linked subcortical laminar heterotopia and lissencephaly syn-
drome. Cell 92, 51–61
15. Yang, H. K., Sundholm-Peters, N. L., Goings, G. E., Walker,
A. S., Hyland, K., and Szele, F. G. (2004) Distribution of
doublecortin expressing cells near the lateral ventricles in the
adult mouse brain. J. Neurosci. Res. 76, 282–295
16. Nacher, J., Crespo, C., and McEwen, B. S. (2001) Doublecortin
expression in the adult rat telencephalon. Eur. J. Neurosci. 14,
629–644
4286 Vol. 23 December 2009 EVANGELISTI ET AL.The FASEB Journal  www.fasebj.org
17. Mizuguchi, M., Qin, J., Yamada, M., Ikeda, K., and Takashima, S.
(1999) High expression of doublecortin and KIAA0369 protein
in fetal brain suggests their specific role in neuronal migration.
Am. J. Pathol. 155, 1713–1721
18. Brown, J. P., Couillard-Despres, S., Cooper-Kuhn, C. M., Win-
kler, J., Aigner, L., and Kuhn, H. G. (2003) Transient expression
of doublecortin during adult neurogenesis. J. Comp. Neurol. 467,
1–10
19. Daou, M. C., Smith, T. W., Litofsky, N. S., Hsieh, C. C., and Ross,
A. H. (2005) Doublecortin is preferentially expressed in invasive
human brain tumours. Acta Neuropathol. 10, 472–480
20. Bernreuther, C., Salein, N., Matschke, J., and Hagel, C. (2006)
Expression of doublecortin in tumours of the central and
peripheral nervous system and in human non-neuronal tissues.
Acta Neuropathol. 111, 247–254
21. Masui, K., Mawatari, S., Suzuki, S. O., and Iwaki, T. (2008)
Evaluation of sensitivity and specificity of doublecortin immu-
nostaining for the detection of infiltrating glioma cells. Brain
Tumor Pathol. 25, 1–7
22. Oltra, S., Martinez, F., Orellana, C., Grau, E., Fernandez, J. M.,
Canete, A., and Castel, V. (2005) The doublecortin gene, a new
molecular marker to detect minimal residual disease in neuro-
blastoma. Diagn. Mol. Pathol. 14, 53–57
23. Messi, E., Florian, M. C., Caccia, C., Zanisi, M., and Maggi, R.
(2008) Retinoic acid reduces human neuroblastoma cell migra-
tion and invasiveness: effects on DCX, LIS1, neurofilaments-68
and vimentin expression. BMC Cancer 8, 30
24. Tissir, F., and Goffinet, A. M. (2003) Reelin and brain develop-
ment. Nat. Rev. Neurosci. 4, 496–505
25. Perrone, G., Vincenti, B., Zagami, M., Santini, D., Panteri, R.,
Flammia, G., Verzì, A., Lepanto, D., Morini, S., Russo, A., Bazan,
V., Tomasino, R. M., Morello, V., Tonini, G., and Rabitti, C.
(2007) Reelin expression in human prostate cancer: a marker of
tumour aggressiveness based on correlation with grade. Mod.
Pathol. 20, 344–351
26. Seigel, G. M., Hackam, A. S., Ganguly, A., Mandell, L. M., and
Gonzalez-Fernandez, F. (2007) Human embryonic and neuro-
nal stem cell markers in retinoblastoma. Mol. Vis. 13, 823–832
27. Wang, Q., Lu, J., Yang, C., Wang, X., Cheng, L., Hu, G., Sun, Y.,
Zhang, X., Wu, and M., Liu, Z. (2002) CASK and its target gene
Reelin were co-upregulated in human esophageal carcinoma.
Cancer Lett. 179, 71–77
28. Encinas, M., Iglesias, M., Llecha, N., and Com’ella, J. X. (1999)
Extracellular-regulated kinases and phosphatidylinositol 3-ki-
nase are involved in brain-derived neurotrophic factor-mediated
survival and neuritogenesis of the neuroblastoma cell line
SH-SY5Y. J. Neurochem. 73, 1409–1421
29. Pfaffl, M. W. (2001) A new mathematical model for relative
quantification in real-time RT-PCR [Online]. Nucleic Acids Res.
29, e45
30. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative
gene expression data using real-time quantitative PCR and the
2(-Delta Delta C(T)) method. Methods 25, 402–408
31. Yarrow, J. C., Perlman, Z. E., Westwood, N. J., and Mitchison,
T. J. (2004) A high-throughput cell migration assay using
scratch wound healing, a comparison of image-based readout
methods. BMC Bio/Technol. 4, 21–30
32. Voigt, A., and Zintl, F. (2003) Effects of retinoic acid on
proliferation, apoptosis, cytotoxicity, migration, and invasion of
neuroblastoma cells. Med. Pediatr. Oncol. 40, 205–213
33. Mehta, K., Fok, J., Miller, F. R., Koul, D., and Sahin, A. A. (2004)
Prognostic significance of tissue transglutaminase in drug resis-
tant and metastatic breast cancer. Clin. Cancer Res. 10, 8068–
8076
34. Shimada, H., Ambrosia, I. M., Dehner, L. P., Hata, J., Joshi,
V. V., and Roald, B. (1999) Terminology and morphologic
criteria of neuroblastic tumours: recommendations by the In-
ternational Neuroblastoma Pathology Committee. Cancer 86,
349–363
35. Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N. L., Castel,
V., Castelberry, R. P., De Bernardi, B., Evans, A. E., Favrot, M.,
and Hedborg, F. (1993) Revisions of the international criteria to
neuroblastoma diagnosis, staging, and response to treatment.
J. Clin. Oncol. 11, 1466–1477
36. Baetge, E. E., Hammang, J. P., Gribkoff, V. K., and Meiri, K. F.
(1992) The role of GAP-43 in the molecular regulation of axon
outgrowth and electrical excitability. Perspect. Dev. Neurobiol. 1,
21–28
37. Sempere, L. F., Freemantle, S., Pitha-Rowe, I., Moss, E.,
Dmitrovsky, E., and Ambros, V. (2004) Expression profiling of
mammalian microRNAs uncovers a subset of brain-expressed
microRNAs with possible roles in murine and human neuronal
differentiation. Genome Biol. 5, R13
38. Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N.,
Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler,
M., Lin, C., Socci, N. D., Hermida, L., Fulci, V., Chiaretti, S., Foa`,
R., Schliwka, J., Fuchs, U., Novosel, A., Mu¨ller, R.-U., Schermer, B.,
Bissels, U., Inman, J., Phan, Q., Chien, M., Weir, D. B., Choksi, R.,
De Vita, G., Frezzetti, D., Trompeter, H.-I., Hornung, V., Teng, G.,
Hartmann, G., Palkovits, M., Di Lauro, R., Wernet, P., Macino,
G., Rogler, C. E., Nagle, J. W., Ju, J., Papavasiliou, F. N., Benzing, T.,
Lichter, P., Tam, W., Brownstein, M. J., Bosio, A., Borkhardt, A.,
Russo, J. J., Sander, C., Zavolan, M., and Tuschl, T. (2007) A
mammalian microRNA expression atlas based on small RNA
library sequencing. Cell 129, 1401–1414
39. Mi, S., Lu, J., Sun, M., Li, Z., Zhang, H., Neilly, M. B., Wang, Y.,
Qian, Z., Jin, J., Zhang, Y., Bohlander, S. K., Le Beau, M. M.,
Larson, R. A., Golub, T. R., Rowley, J. D., and Chen, J. (2007)
MicroRNA expression signatures accurately discriminate acute
lymphoblastic leukemia from acute myeloid leukemia. Proc.
Natl. Acad. Sci. U. S. A. 104, 19971–19976
40. Chen, Y., Kundakovic, M., Agis-Balboa, R. C., Pinna, G., and
Grayson, D. R. (2007) Induction of the reelin promoter by
retinoic acid is mediated by Sp1. J. Neurochem. 103, 650–665
41. Sato, N., Fukushima, N., Chang, R., Matsubayashi, H., and
Goggins, M. (2006) Differential and epigenetic gene expression
profiling identifies frequent disruption of the RELN pathway in
pancreatic cancers. Gastroenterology 130, 548–565
42. Chen, Y., and Stallings, R. L. (2007) Differential patterns of
MicroRNA expression in neuroblastoma are correlated with prog-
nosis, differentiation, and apoptosis. Cancer Res. 67, 976–983
43. Zhang, Y., Chao, T., Li, R., Liu, W., Chen, Y., Yan, X., Gong, Y.,
Yin, B., Liu, W., Qiang, B., Zhao, J., Yuan, J., and Peng, X. (2009)
MicroRNA-128 inhibits glioma cells proliferation by targeting
transcription factor E2F3a. J. Mol. Med. 87, 43–51
44. Hoebeeck, J., Michels, E., Menten, B., Van Roy, N., Eggert, A.,
Schramm, A., De Preter, K., Yigit, N., De Smet, E., De Paepe, A.,
Laureys, G., Vandesompele, J., and Speleman, F. (2007) High
resolution tiling-path BAC array deletion mapping suggests com-
monly involved 3p21–p22 tumour suppressor genes in neuroblas-
toma and more frequent tumours. Int. J. Cancer 120, 533–538
45. Mosse, Y. P., Diskin, S. J., Wasserman, N., Rinaldi, K., Attiyeh,
E. F., Cole, K., Jagannathan, J., Bhambhani, K., Winter, C., and
Maris, J. M. (2007) Neuroblastomas have distinct genomic DNA
profiles that predict clinical phenotype and regional gene
expression. Genes Chromosomes Cancer 46, 936–949
Received for publication April 6, 2009.
Accepted for publication August 6, 2009.
4287MIR-128 AND NEUROBLASTOMA AGGRESSIVENESS
